Oppenheimer Asset Management’s State Street SPDR S&P Biotech ETF XBI Stock Holding History

Oppenheimer Asset Management’s Portfolio XBI Stock Details XBI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$5.77M	Buy	+36,464	New	+$4.93M	0.06%	333
2022 Q4	–	Sell	-31,627	Closed	-$2.51M	–	1186
2022 Q3	$2.51M	Sell	31,627 -8	-0%	-$674	0.04%	400
2022 Q2	$2.35M	Buy	31,635 +3	+0%	+$225	0.04%	424
2022 Q1	$2.84M	Sell	31,632 -4,545	-13%	-$420K	0.04%	427
2021 Q4	$4.05M	Sell	36,177 -576	-2%	-$69.5K	0.05%	348
2021 Q3	$4.62M	Buy	36,753 +3,329	+10%	+$429K	0.07%	317
2021 Q2	$4.53M	Buy	33,424 +848	+3%	+$111K	0.06%	319
2021 Q1	$4.42M	Buy	32,576 +658	+2%	+$98.5K	0.07%	309
2020 Q4	$4.49M	Sell	31,918 -1,414	-4%	-$181K	0.08%	293
2020 Q3	$3.71M	Buy	33,332 +28,531	+594%	+$3.2M	0.07%	299
2020 Q2	$537K	Sell	4,801 -432	-8%	-$42.5K	0.01%	784
2020 Q1	$405K	Sell	5,233 -315	-6%	-$27.9K	0.01%	795
2019 Q4	$528K	Sell	5,548 -75	-1%	-$6.49K	0.01%	803
2019 Q3	$429K	Sell	5,623 -297	-5%	-$24.7K	0.01%	845
2019 Q2	$519K	Sell	5,920 -366	-6%	-$31.2K	0.01%	804
2019 Q1	$569K	Sell	6,286 -410	-6%	-$34.9K	0.01%	764
2018 Q4	$480K	Sell	6,696 -281	-4%	-$22.6K	0.01%	778
2018 Q3	$669K	Sell	6,977 -192	-3%	-$18.6K	0.01%	726
2018 Q2	$682K	Sell	7,169 -105	-1%	-$9.65K	0.02%	705
2018 Q1	$638K	Sell	7,274 -1,436	-16%	-$131K	0.02%	721
2017 Q4	$754K	Hold	8,710	–	–	0.02%	684
2017 Q3	$754K	Buy	8,710 +6,923	+387%	+$555K	0.02%	687
2017 Q2	$138K	Sell	1,787 -2,352	-57%	-$167K	﹤0.01%	1118
2017 Q1	$287K	Buy	+4,139	New	+$278K	0.01%	946

Other funds holding XBI

BNP Paribas Financial Markets Paris, France $289B AUM 60.46% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Healthcare of Ontario Pension Plan (HOOPP) Trust Fund Toronto, Ontario, Canada $71.2B AUM 48.86% 1-Year Est. Return

Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Barclays London, United Kingdom $521B AUM 51.41% 1-Year Est. Return

JFG

Jefferies Financial Group New York $15.2B AUM 55.75% 1-Year Est. Return

Oppenheimer Asset Management's XBI Position: Q2 2026 in Review

Oppenheimer Asset Management opened a new position in State Street SPDR S&P Biotech ETF (XBI) in Q2 2026: 36,464 shares worth $5.77M. The stake represents 0.06% of the portfolio and ranks #333 among its holdings. This is a return to the name: Oppenheimer Asset Management previously reported a position in XBI as recently as Q3 2022.

Oppenheimer Asset Management first reported a position in XBI in Q1 2017 and has held it in 24 quarters since. 936 funds tracked by Wall St. Rank hold XBI as of Q2 2026.

Oppenheimer Asset Management held 36,464 shares of State Street SPDR S&P Biotech ETF worth $5.77M as of Q2 2026.
State Street SPDR S&P Biotech ETF was a new Oppenheimer Asset Management position in Q2 2026.
State Street SPDR S&P Biotech ETF made up 0.06% of Oppenheimer Asset Management's portfolio in Q2 2026, its #333 holding.
Oppenheimer Asset Management first reported a position in State Street SPDR S&P Biotech ETF in Q1 2017 and has held it in 24 quarters since.
936 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q2 2026.

Based on Oppenheimer Asset Management's 13F filing for Q2 2026, filed 3 Aug 2026.